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Background: Acute kidney injury is a common and devastating complication of critical illness, for which renal
replacement therapy is frequently needed to manage severe cases. While a recent systematic review suggested that
“earlier” initiation of renal replacement therapy improves survival, completed trials are limited due to small size,
single-centre status, and use of variable definitions to define “early” renal replacement therapy initiation.
Methods/design: This is an open-label pilot randomized controlled trial. One hundred critically ill patients with
severe acute kidney injury will be randomly allocated 1:1 to receive “accelerated” initiation of renal replacement
therapy or “standard” initiation at 12 centers across Canada. In the accelerated arm, participants will have a venous
catheter placed and renal replacement therapy will be initiated within 12 hours of fulfilling eligibility. In the
standard initiation arm, participants will be monitored over 7 days to identify indications for renal replacement
therapy. For participants in the standard arm with persistent acute kidney injury, defined as a serum creatinine not
declining >50% from the value at the time of eligibility, the initiation of RRT will be discouraged unless one or
more of the following criteria are fulfilled: serum potassium ≥6.0 mmol/L; serum bicarbonate ≤10 mmol/L; severe
respiratory failure (PaO2/FiO2<200) or persisting acute kidney injury for ≥72 hours after fulfilling eligibility. The
inclusion criteria are designed to identify a population of critically ill adults with severe acute kidney injury who are
likely to need renal replacement therapy during their hospitalization, but not immediately. The primary outcome is
protocol adherence (>90%). Secondary outcomes include measures of feasibility (proportion of eligible patients
enrolled in the trial, proportion of enrolled patients followed to 90 days for assessment of vital status and the need
for renal replacement therapy) and safety (occurrence of adverse events).
Discussion: The optimal timing of renal replacement therapy initiation in patients with severe acute kidney injury
remains uncertain, representing an important knowledge gap and a priority for high-quality research. This pilot trial
is necessary to establish protocol feasibility, confirm the safety of participants and obtain estimated events rates for
design of a large definitive trial.
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Acute kidney injury (AKI) is a common complication in
critically ill patients. Among those with severe AKI, 50
to 70% will receive renal replacement therapy (RRT) [1].
RRT increases the complexity and costs of care and is
associated with death, with case-fatality rates commonly
exceeding 60% [1,2], and dialysis dependence among
survivors [2-4].
Methods of providing RRT to patients in the ICU vary
widely, reflecting uncertainty surrounding many aspects
of this therapy [5,6]. It is generally understood that life-
threatening AKI complications, such as severe hyper-
kalemia, profound acidosis and fluid overload resulting
in respiratory failure, are absolute indications for RRT.
However, outside of these indications, the optimal time
to start RRT in critically ill patients with severe AKI re-
mains unknown. Early initiation of RRT has the intuitive
appeal of avoiding life-threatening AKI complications;
however, RRT is not without complications and costs
[7,8], and in the setting of chronic dialysis for end-stage
renal disease, no evidence of benefit was found with
earlier start times [9].
We recently performed a systematic review of the ef-
fect of RRT timing on mortality in adult critically ill pa-
tients, and included 15 studies published between 1999
and 2010 [10]. In a pooled analysis limited by low meth-
odological quality of the included studies and important
statistical heterogeneity, early (versus later) initiation of
RRT was associated with a significantly reduced odds of
death (odds ratio 0.45, 95% CI 0.28, 0.72). The largest
published randomized controlled trial (RCT) (n=106) of
RRT timing found no difference in mortality; however, it
was underpowered to detect a clinically implausible ab-
solute difference in mortality of less than 40% [11]. For
comparison, the large multi-cente rtrial, Randomized
Evaluation of Normal versus Augmented Level Renal
Replacement Therapy (RENAL),enrolled 1,508 critically
ill patients with severe AKI and was powered to detect a
minimal difference in 90-day mortality of 7.5% [12].
Given the limitations of published studies, a large and
methodologically rigorous RCT is needed to evaluate the
impact on survival and renal recovery of earlier versus
current usual criteria for RRT initiation in critically ill
adults with severe AKI. This question has also been
identified as a top research priority by the Acute Kidney
Injury Network [13] and endorsed by intensivists and
nephrologists [14].
Our objective is to conduct a Canadian multi-centerRCT
in critically ill patients with severe AKI, comparing the
effect of accelerated versus standard RRT initiation on 90-
day mortality and dialysis dependence among 90-day survi-
vors. To support this trial, we propose to perform a pilot
trial to evaluate protocol adherence, estimate recruitment




The design is an open-label, multi-center, pilot, ran-
domized controlled trial of accelerated versus standard
initiation of RRT initiation in critically ill patients with
severe AKI.
Setting
The setting is the ICU at 12 academic hospitals across
Canada. Site investigators are listed in Additional file 1.
Population
Eligible participants will fulfill all inclusion and no exclu-
sion criteria (see Additional file 2).
Inclusion criteria
The inclusion criteria are designed to identify a popula-
tion of critically ill adults with severe AKI who have an
increased likelihood of receiving RRT during their
hospitalization, but who do not have urgent indications
for the initiation of RRT at the time of fulfilling eligibil-
ity criteria. All six criteria must be fulfilled at the time
of screening:
1. Age ≥18 years.
2. Admission to an ICU.
3. Evidence of kidney dysfunction (serum creatinine
above the upper threshold of normal for commercially
available laboratory assays (women ≥100 μmol/L;
men ≥130 μmol/L)
4. Evidence of severe AKI based on at least two of the
following three criteria:
i. A 2-fold increase in serum creatinine during
hospitalization or from a known pre-
hospitalization baseline with current creatinine
no less than 25 μmol/L below peak (consistent
with the Risk, Injury, Failure, Loss, End-stage
renal failure (RIFLE) INJURY category of AKI);
ii. Oliguria as defined by urine output <6 mL/kg
over the preceding 12 hours (consistent with
RIFLE category of AKI);
iii. If only one of two above criteria for severe AKI
are met and all other eligibility criteria are
fulfilled, a whole-blood Cardiorenal Neutrophil
Gelatinase-Associated Lipocalin™ (NGAL)(Alere
Inc., San Diego, CA, USA) ≥400 ng/mL.
5. Likelihood that an absolute indication for RRT will
not arise in the subsequent 24 hours based on the
most recent blood laboratory values:
i. Serum potassium ≤5.5 mmol/L, and
ii. Serum bicarbonate ≥15 mmol/L.
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for this criterion is to ensure adequate volume
resuscitation and mitigate enrollment of patients
with hypovolemia or AKI that will readily improve
with fluid administration.
NGAL testing for eligibility
NGAL is a novel biomarker that is upregulated early in
the course of AKI [15]. Whole blood (0.25 to 0.50 mL)
will be tested using a fluorescence immunoassay that
operates on the Triage™ platform (Alere Inc.) and yields
quantitative results within 15 to 20 minutes. NGAL may
detect AKI prior to excursions in the serum creatinine
[16,17] and has been found useful for discriminating be-
tween patients whose elevated serum creatinine values
are due to established acute kidney damage (that is, the
target population for this trial) compared to chronic kid-
ney disease or uncomplicated volume contraction [18].
A recent meta-analysis also found that plasma NGAL
concentrations predict worsening AKI and the receipt of
RRT with an estimated area under the receiver operator
curve of 0.78 [19]. We chose a cutoff value for NGAL of
400 ng/mL based on data from recently published studies
[20,21] which found the operating characteristics for a
serum NGAL of 417 ng/mL for predicting the need for
RRT (that is, development of RIFLE-Failure AKI) to be as
follows: sensitivity 0.70; specificity 0.90; positive predictive
value 0.40; and negative predictive value 0.97. The high
negative predictive value identifies this threshold as a spe-
cific predictor for subsequently receiving RRT [20,21].
Exclusion criteria
1. Lack of commitment to ongoing life support,
including RRT.
2. Presence of a drug overdose that necessitates
initiation of RRT.
3. Any RRT within the previous 2 months.
4. Presence or clinical suspicion of renal obstruction,
rapidly progressive glomerulonephritis, vasculitis, or
acute interstitial nephritis.
5. Known pre-hospitalization advanced chronic kidney
disease, defined by an estimated glomerular filtration
rate <30 mL/minute/1.73 m2, or chronic RRT.
6. Kidney transplant within the past 365 days.
7. Time since first doubling of serum creatinine has
exceeded 48 hours.
8. Clinician(s) caring for patient believe(s) that
immediate RRT is absolutely mandated.
9. Clinician(s) caring for patient believe(s) that deferral
of RRT initiation is mandated.
10. Patient or substitute decision maker is unable to
provide consent within 12 hours of determination of
study eligibility.Eligible, non-randomized patients
Eligible non-randomized patients will be those who meet
all inclusion criteria but are not included in the trial for
the following reasons:
1. A doubling of serum creatinine that has exceeded 48
hours at the time of screening (exclusion 7);
2. Clinician(s) belief that either immediate RRT is
absolutely mandated (exclusion 8) or deferral of RRT
initiation (exclusion 9) is absolutely mandated; or
3. Refusal of consent or inability to obtain consent
within 12 hours of patient meeting eligibility criteria
(exclusion 10).
We will document reasons leading to non-inclusion of
these otherwise eligible patients. For these patients, we
will collect data on kidney function at baseline and at
the time of eligibility, severity of illness at the time of eli-
gibility, receipt of RRT in hospital and need for RRT at
hospital discharge, and vital status at ICU and hospital
discharge. The collection of these data will enable com-
parisons with randomized patients to assess threats to
the generalizability of the trial results.
Screening process
Research coordinators will screen patients in each study
ICU for eligibility twice each weekday, in the morning
and afternoon. Given the dynamic nature of the inclu-
sion criteria, individuals who are not initially eligible for
the trial will be re-screened each day. Research coordi-
nators will discuss all patients who meet inclusion cri-
teria, without an exclusion criterion, with the attending
intensivist and, if applicable, the attending nephrologist.
Ethics and consent
The Health Research Ethics Boards (HREB) at the
University of Alberta (Edmonton) and St. Michael’s Hos-
pital (Toronto), along with those at each participating
site, reviewed and approved the study (see Additional file
3). Research coordinators will approach eligible patients
or their substitute decision maker (SDM), in the event of
patient incapacity, for informed consent (see Additional
file 4). If the SDM provides consent but the patient be-
comes capable prior to the end of the follow-up period,
the research coordinator will seek consent directly from
the patient, who will have the option of withdrawing
from the study. If an SDM is contactable by telephone
but is not able to come in person to sign the consent
form, steps will be taken to obtain telephone consent.
At four sites where this study has Research Ethics Board
(REB) approval, patients who are eligible but incapable of
providing consent and for whom an SDM is not available
may be randomized through a process of deferred consent
(see Additional file 5). In this circumstance, the research
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enrollment, and ask the SDM to affirm or withdraw con-
sent for the patient’s participation. In addition, once the
participant regains capacity, he/she will be asked to affirm
or withdraw consent for the trial.
Co-enrollment
Patients recruited to the study, STtandard versus Accel-
erated initiation of Renal Replacement Therapy in Acute
Kidney Injury (STARRT-AKI), may also be enrolled in
other studies provided that the steering committee has
reviewed the protocol and determined that there is no
interference with the timing of RRT initiation mandated
by the STARRT-AKI protocol. Prior survey findings have
shown clinical researchers’ support for trial co-enrollment
of critically ill patients [22].
Randomization process
Participants will be randomly allocated in a ratio of 1:1,
stratified by study center using variable block sizes undis-
closed to site study personnel, to accelerated or standard
initiation of RRT. The study statistician at the methods
centre (Applied Health Research Centre (AHRC), St.
Michael’s Hospital, Toronto, Canada) will generate the
random allocation sequence using computer software.
Randomization information for each site will be contained
in locally held sequentially numbered, opaque, sealed en-
velopes. Envelopes are to be opened in numeric sequence.
Interventions
Accelerated RRT initiation (experimental arm):a catheter
will be placed by the treating ICU or Nephrology team
and RRT initiated as soon as possible, and within 12
hours of eligibility. This 12-hour window includes the
time needed to obtain consent.
Standard RRT initiation (control arm):the study team
will follow patients for 7 days to identify potential indi-
cations for RRT. For patients with persistent AKI (serum
creatinine has not declined by more than 50% from
value at time of eligibility), the protocol discourages
RRT initiation unless one or more of the following
criteria are met:
1. Serum potassium ≥6.0 mmol/L, or
2. Serum bicarbonate ≤10 mmol/L, or
3. Severe respiratory failure, defined as arterial partial
pressure of oxygen(PaO2)/inspired oxygen fraction
(FiO2)<200 and bilateral infiltrates on the chest
radiograph, or
4. Persistent AKI (as defined above) 72 hours after
eligibility.
Notwithstanding these recommendations, RRT in the
control arm may be commenced at anytime, provided >12hours have elapsed since the patient met eligibility criteria,
at the discretion of the attending physician(s). This will
not be considered a protocol deviation. If this occurs, the
physician will be asked to specify the primary reason for
initiating RRT on that day. If RRT is initiated within 12
hours of eligibility, the clinician will also be asked to pro-
vide primary reason(s) for this protocol violation.
Renal replacement therapy delivery
Other than the study intervention (that is, differential
timing of RRT initiation), all RRT delivered to patients
in both treatment arms will follow current clinical practice
guidelines [23]. The three commonly used RRT modalities
may be used in this study: intermittent hemodialysis
(IHD), sustained low efficiency dialysis (SLED), and con-
tinuous renal replacement therapy (CRRT). These are
summarized in Table 1. The initial RRT modality will be
guided by hemodynamic status at the time the patient is
ready to start RRT using the cardiovascular component of
the Sequential Organ Failure Assessment score (SOFACV)
[24]. Following the initiation of RRT, modality switches
will be guided by the patient’s hemodynamic profile, as
done in a recent large trial [25].
Cessation of renal replacement therapy
RRT may be discontinued due to:
1. Withdrawal of renal support in the context of a
change in the overall goals of care for the patient, or
2. Kidney function recovery with no need for RRT,
assessed at least 48 hours after the last RRT session
and defined by:
i. Decline in serum creatinine by ≥50 μmol/L on
two blood tests separated by >12 hours with no
RRT during the 48 hours from the last RRT
session to the time of assessment; or
ii. Urine output >6 mL/kg during any 12-hour
period during the 48-hour period of evaluation,
with most recent serum potassium <5.5 mmol/L
and most recent serum bicarbonate >18 mmol/L.Co-interventions
The administration of volume expanders, inotropes, and
vasopressors for hemodynamic support will be at the dis-
cretion of the ICU team. Vital signs and routine blood work
will be performed and documented as per usual practice.
Monitoring and follow-up
We will collect data on all RRT treatments, adverse
events and serious adverse events (defined below) for 14
days after randomization. We will determine vital status
and need for RRT among survivors at 90 days following
randomization through chart review and direct contact
with patients or SDMs, if necessary.
Table 1 Delivery of renal replacement therapy in the trial
Intermittent hemodialysis Sustained low-efficiency dialysis Continuous renal replacement therapy
Patient hemodynamic profile Off all vasopressors and
inotropes (SOFAcv <2)
Receiving any dose of vasopressor
or inotrope (SOFAcv ≥2)
Receiving any dose of vasopressor or
inotrope (SOFAcv ≥2)
Minimum session duration (hrs) 3 8 24
Minimum frequency 3 times/week 3 times/week NA
Blood flow target (mL/min) 200 to 400 200 to 300 100 to 250
Dialysate flow (mL/min) 500 to 800 200 to 400 NA
Total effluent (mL/kg/hr) NA NA ≥25
Anticoagulation options Heparin Heparin Heparin
None None None
Regional citrate anticoagulation
Fluid removal rate To be determined by the nephrologist and/or critical care physician
This table outlines guidelines for renal replacement therapy prescription by modality for randomized participants. NA, not applicable; SOFAcv, cardiovascular
component of the Sequential Organ Failure Assessment score [22].
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Our primary outcome is protocol adherence, defined as
>90% of participants adhering to their allocated treat-
ment (that is, in the accelerated arm, starting RRT
within 12 hours of eligibility; and in the standard initi-
ation arm, starting RRT at least 12 hours following eligi-
bility, considering patients who ultimately receive RRT).
Compliance with protocol adherence will be captured
for all randomized patients. For those allocated to the
standard arm, we will ascertain the time of starting RRT
(if started) relative to the time of fulfilling eligibility, and
the indications for starting RRT. We will capture the
specific reasons for non-compliance and crossover to
starting RRT prior to 12 hours in those patients allo-
cated to the standard arm.
Secondary outcomes include:
1. Proportion of eligible patients who are successfully
enrolled in the trial (feasibility objective, >50% of
eligible patients).
2. Proportion of enrolled patients for whom vital status
and need for RRT can be determined at 90 days
(feasibility objective, >95% of participants).
3. Serious adverse events potentially attributable to the
study treatment, including death, vascular-access
complications and complications associated with the
delivery of RRT occurring up to day 14.Sample size
Our proposed sample size (n=100) will enable us to de-
tect the primary feasibility target of 90% protocol adher-
ence with a 95% CI of 79 to 96%. The lower limit of this
CI would be the minimum acceptable in the proposed
large definitive trial. Furthermore, assuming a normal
distribution for the time from randomization to RRTinitiation in our trial and SD estimated from a previous
trial (SD 4.96) [11], we estimate that our sample size will
have >95% power to detect a difference of at least 24
hours in time to RRT initiation between the accelerated
and standard arms. Considering secondary endpoints,
our sample size will permit calculation of CIs of 43 to
57% for the enrollment of 50% of eligible patients and
89 to 98% for achievement of 95% followup to 90 days.Analysis
Analysis will be intention-to-treat. The primary feasibil-
ity analysis will evaluate the proportion (95% CI) of all
randomized patients adhering to their allocated treat-
ment. The secondary feasibility analyses will evaluate the
proportion (95% CI) of all screened eligible participants
who are enrolled, and the proportion (95% CI) of enrolled
patients having vital status and RRT dependence at 90
days ascertained. The secondary safety analysis will evalu-
ate differences in the incidence of adverse events between
the accelerated and standard groups. Tertiary analyses of
patient-centered and health-resource utilization outcomes
between the groups will be performed, including mortality
through day 90, need for RRT through day 90, a compos-
ite of major adverse kidney events (MAKE), duration of
ICU stay, duration of hospitalization and hospital re-
admission through day 90.
Descriptive statistics, boxplots and histograms will be
used to analyze individual baseline variables by accelerated
or standard arms. Normally or near normally distributed,
non-correlated variables will be reported as means with
SD and compared using the appropriate Student’s t-test.
Non-normally distributed, non-correlated continuous data
will be reported as medians with IQRs and compared
using the Mann Whitney U-test. Non-correlated categor-
ical data, including the tertiary analyses such as mortality
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will be reported as proportions and compared using
Fisher’s exact test. Normally distributed correlated data
will be analyzed by repeated measures analysis of variance
(ANOVA). Non-normally distributed correlated data will
be analyzed by the Friedman test. Correlated categorical
data will be analyzed by generalized estimating equations.
A P-value <0.05 will be considered significant. All statis-
tical tests will be two-sided.Adverse events
Adverse events that are potentially attributable to the study
treatment, including death, vascular-access complications
(that is, hemorrhage, thrombosis, or infection) and compli-
cations associated with the delivery of RRT (that is,
dialysis-associated hypotension, electrolyte abnormalities,
and arrhythmias) will be documented during the first 14
days after randomization (Table 2). In addition, all serious
adverse events that occur within 14 days after rando-
mization are to be documented and reported, regardless of
direct connection to the study. A serious adverse event is
defined as: 1) any event that is fatal or immediately life-
threatening, permanently disabling, severely incapacitating,
or requires prolonged inpatient hospitalization, or 2) any
event that may jeopardize the patient and requires medical
or surgical intervention to prevent one of the outcomesTable 2 Reportable adverse events
Related to renal replacement therapy (RRT)
RRT-associated hypotension:
Drop in blood pressure requiring one of: initiation of a vasopressor
during RRT session, or need to escalate dose of a vasopressor during
the RRT session, or premature discontinuation of RRT session, or any
other intervention to stabilize blood pressure.
Severe hypophosphatemia:
Serum phosphorus <0.5 mmol/L
Severe hypokalemia:
Serum potassium <3.0 mmol/L
Severe hypocalcemia:




New atrial (excluding sinus tachycardia or sinus arrhythmia) or
ventricular arrhythmia that develops during RRT and was not present
prior to initiation of RRT
Seizure
Hemorrhage in patient receiving RRT with heparin-based
anticoagulation
This table outlines the adverse events that are to be documented and reported durlisted above. We will track all adverse events until reso-
lution or day 90, whichever comes first.
Trial oversight
Steering Committee:the Committee will meet monthly by
teleconference to review and address operational issues.
Coordinating Center:the AHRC of the Keenan Re-
search Centre in the Li Ka-Shing Knowledge Institute of
St. Michael’s Hospital, University of Toronto, will serve
as the central trial coordination and data management
center. AHRC will work closely with the study sponsor
and Steering Committee to coordinate trial activities, and
will be responsible for managing trial sites, obtaining regu-
latory approvals, safety reporting, maintaining and archiv-
ing trial documentation, sourcing and distributing trial
materials, developing electronic case report forms, train-
ing trial staff, performing data validation and monitoring
activities, performing statistical programming and ana-
lysis, and providing results of analyses.
Data and Safety Monitoring Board (DSMB): the three-
member DSMB is comprised of experts in nephrology,
critical care, and clinical research. The DSMB will meet
by teleconference every 6 months while the trial is ac-
tively recruiting. The primary role of the DSMB will be
to monitor adverse events among trial participants. The
DSMB will assess whether these events are linked to
participation in the trial or to any aspect of the studyRelated to central venous catheter (CVC)
Hemorrhage at the site of CVC insertion:
Bleeding requiring transfusion of ≥1 unit(s) of packed red blood cells
and/or surgical intervention/repair within 12 hours following insertion
CVC-associated bloodstream infection:
Bacteremia in 2 blood culture sets with no proven alternative source
for bacteremia or culture-positive recovery of the same organism from
the dialysis catheter upon removal
Ultrasonographically-confirmed thrombus attributed to CVC
Pneumothorax (for catheters placed in the internal jugular or
subclavian positions)
Hemothorax (for catheters placed in the internal jugular or subclavian
positions)
Air embolism
Inadvertent arterial puncture at time of CVC insertion
Other CVC-related adverse events
ing the first 14 days after randomization.
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Committee (see Additional file 6). The trial has been
reviewed and endorsed by the Canadian Critical Care Trials
Group (CCCTG).
Discussion
The optimal timing of RRT initiation for severe AKI is
currently unknown. Data from observational studies and
recent systematic reviews [9,10,26-31] suggest that earl-
ier commencement of RRT may benefit patients, but
high-quality evidence to support this decision is cur-
rently lacking. Prior to starting a large, definitive RCT
addressing this question, a pilot study is necessary to de-
termine the feasibility of participant recruitment and
protocol implementation in addition to assessing safety.
Strengths in the design of our pilot trial include carefully
defined feasibility objectives, a clinically grounded prag-
matic approach to enrollment and to the delivery of RRT,
methods to reduce bias (allocation concealment, objective
outcomes, and steps to ensure complete follow-up), re-
cruitment from centers experienced in critical care and
RRT research, and incorporation of alternate consent
models. These steps will reliably inform decision-making
regarding the design of the definitive trial. In addition, our
inclusion criteria acknowledge that conventional metrics
of kidney function poorly predict the need for RRT.
Accordingly, a novel and unique aspect of our trial is the
incorporation of a kidney-damage-specific biomarker,
NGAL, in the patient selection process.
The design of this pilot RCT has limitations. First, the
inclusion criterion of central venous pressure ≥8 mmHg
does not reliably identify patients who are adequately
volume resuscitated, but this measurement is more likely
to be available than other functional hemodynamic
assessments [32]. Second, although we have provided
general recommendations that reflect prevailing clinical
practice and are consistent with current clinical practice
guidelines, we have not protocolized other aspects of
RRT delivery, such as clearance and modality, in the ab-
sence of data confirming the clear superiority of a par-
ticular approach [33,34]. Although caregivers are not
blinded in this trial, clinician awareness of treatment as-
signment in two recent RCTs of RRT in the ICU did not
compromise study validity [12,25]. Third, it is possible
that attending intensivists and nephrologists will have
firm beliefs on the timing of RRT initiation and decline
to allow their patients to be enrolled. However, a survey
of Canadian intensivists and nephrologists (n=180) found
that the large majority (93.7%) believed it would be ethical
to randomize patients into such a trial [14].
RRT is an important and core life-support technology
for critically ill patients with AKI, but it is also labor-
intensive, expensive, and associated with complications.
The timing of its initiation is a fundamental part of theRRT prescription, but there are no high-quality data to
guide clinicians on when they make this decision [11].
The STARRT-AKI pilot RCT is a vital first step to filling
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